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Purpose: Evaluation of relationships between survival time of patients with advanced, non-
resectable non-small cell lung cancer (NSCLC) and telomerase activity in aspirates, collected
from primary lung tumours, and serum p53 protein levels.
Material and methods: The study group consisted of 52 patients with advanced (stage IIIB and
IV) non-small cell lung cancer. In all of them, transthoracic fine-needle biopsy (TFNB) of focal
pulmonary lesion was performed. The aspirates were subjected to telomerase activity by the
PCReELISA PLUS method and serum levels of p53 protein were determined by the ELISA
method. Additionally, clinical advancement of cancer and the time period of survival were as-
sessed in the studied group. KaplaneMeyer method and Cox analysis were used for statistical
evaluation of survival prognosis.
Results: Increased telomerase activity was observed in 42 (81%) of the patients with non-
resectable non-small cell lung cancer. Elevated concentrations of serum p53 protein were
found in 28 (54%) of the participants. The following death rates were noted during the entire
study period: twenty-three (23) (62%), out of 37 patients with increased telomerase activity, 7
(47%), out of 15 without detectable telomerase activity in primary lung tumour, 16 (57%), out
of 28 subjects with increased serum levels of p53 protein and 14 (58%), out of 24 with no
increased serum levels of p53.
A significant relationship was observed in Cox hazard analysis between the time of survival
and telomerase activity, while no such relationship was observed between the survival time
period and serum p53 protein levels or sex, age, primary lung tumour size, lymph node status
or development of distant metastases.itute of Health Service, Szaserow 128, Warsaw, Poland. Tel.: þ48 22 6816581; fax: þ48 22 6816588.
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predictor of patients’ survival than serum levels of p53 protein. The assessment of telomerase
activity supplements in the prognosis of survival in the course of non-resectable NSCLC.
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Lung cancer is the most common malignant tumour all over
the world and is the main cause of deaths related to
neoplastic diseases. More than 80% of cases include non-
small cell lung cancer (NSCLC).1 In the majority of cases,
NSCLC develops peripherally in the lung parenchyma and,
therefore, transthoracic fine-needle biopsy (TFNB) is one of
the principal methods of cytological diagnostics of such
tumours. It is believed that in patients with NSCLC, the
rates of activity of certain molecular markers may be
helpful prognostic factors, regarding both the overall and
free-of-recurrence survival periods.2e5 Telomerase and p53
suppressor gene belong to the most important pathways of
carcinogenesis in lung malignancies.6e8
Telomerase is a specific DNA polymerase, consisting of
a protein component, comprising telomerase reverse tran-
scriptase and telomerase-associated protein 1 and an RNA
component, which is a template for the elongation of
telomeric repeat sequences, located at the ends of DNA.8,9
High-telomerase activity is characteristic, first of all, for
cells of malignant tumours, being associated with their
uncontrolled proliferation.9 The p53 tumour suppressor
gene is involved in the control of cell growth and pro-
grammed cell death.7,8 The aim of the reported study was
to assess the relationship between the survival of patients
with advanced, non-resectable NSCLC and telomerase
activity in aspirates, collected from primary lung tumours,
as well as serum levels of p53 protein.Material and methods
Patients with non-resectable (stage IIIB and IV), non-small
cell lung cancer have been enrolled to the study. In each
patient, TNFB was done [Becton Dickinson needle 0.7 mm in
diameter] under fluoroscopy control. After radiologically
confirmed localisation of the needle into the tumour, an
aspirate was collected and divided into two equal speci-
mens for cytological and molecular examinations. The
aspirates for cytological examination were smeared on
defatted slides, fixed in 95% ethyl alcohol, and stained with
eosin and haematoxylin. The specimens were separately
evaluated by two pathologists and the final diagnosis was
obtained by consensus between them. The pathologists
were not informed about the level of telomerase activity in
the specimens at any stage before the final diagnosis.
The aspirates for telomerase activity assessment were
immediately placed in 1 ml probes and deeply frozen [at
70 C]. PCR-ELISAPLUS (ROCHE Molecular Biochemicals,
Mannheim, Germany) method was used for the assessment
of telomerase activity, as described below:10
After defrosting, the aspirates were homogenized in
200 ml ice-cooled Lysis reagent. The lysate was centrifuged
at 16000g for 20 min at 4 C. A volume of 175 ml of thesupernatant was gently removed and its protein concentra-
tion measured with a Bio Rad Protein Assay Kit. Each
supernatant was divided into two aliquots: one, inactivated
at 85 C for 10 min, was used as a negative control, while the
other one was used to evaluate telomerase activity. A 3 mg
volume of the protein extract was used for each assay. The
telomerase activity assessment was done, according to the
Telomeric Repeat Amplification Protocol [TRAP] method,
consisting in amplification of telomeric sequences, added by
telomerase to the 30 end of biotin-labelled synthetic primer.
Those elongation products, as well as the Internal standard
[IS], which constituted a positive control, included in the
same reaction vessel, were amplified, using appropriate
primers. The PCR products were split into two aliquots,
denaturated and hybridized to digoxigenin-labelled probes,
specific for the telomeric repeats and for the IS, respec-
tively. The resulting products were immobilized via the
biotin label to a streptavidin-coated micro titre plate. The
immobilized amplicons were then detected with an anti-
digoxigenin antibody, conjugated to horseradish peroxidase
and sensitive peroxidase substrate. The absorbance of the
samples was measured, using an ELISA reader with 450 nm
wavelength. The samples were considered as telomerase
positive if the difference in absorbance was higher than the
background activity. As proposed by the manufacturer,
relative telomerase activity units (RTA) were used for the
quantitative assessment of telomerase activity.10
Seven ml of venous blood was collected from each
participant. The photometric one-step-enzyme-
immunoassay method for the quantification of circulating
p53 [ROCHE Molecular Biochemicals, Mannheim, Germany]
was used.11 The assay is based on the quantitative ‘‘sand-
wich ELISA’’ principle. P53 activity was measured twice in
each sample, and its mean value was used for further
analysis. The samples with signal twice higher than the
zero-standard signal were considered as positive. Serum
p53 concentrations were expressed in pg/ml.
The survival of patients was evaluated with respect to
telomerase activity in TFNB aspirates and serum p53 levels
by the KaplaneMeier method. Patients with the status
which could have a significant influence on their survival,
i.e., complete respiratory failure or severe blood circula-
tion failure, haemoglobin concentration below 11 g/dl,
hypoalbuminemia (<3 g/dl), serum lactate dehydrogenase
concentration above 150 U/l, platelet count above 600 g/l,
hypercalcemia (>2.75 mmol/l) or bad general status (3 at
Zubrod’s scale) were excluded.12e17 Patients with malig-
nant neoplastic diseases during previous 5 years, as well as
patients with NSCLC, recognised before TFNB were not
included, either. Deaths because of cancer or its recur-
rence during the study period were qualified as complete
observation and analyzed separately. Tumour size, lymph
node invasion and distant metastases were determined in
all the cancer subjects according to International System
for Staging Lung Cancer.1,18 In patients who undergone
Table 1 Overall survival of patients with non-resectable NSCLC in relation to telomerase activity and p53 protein expression.
Number of patients Observation period
Mean overall
survival (95% CI) (days)
Number of complete
observations (deaths), n (%)
Telomerase () 8 330.6 (244.2e417.0) 4 out of 8 (50.0%)
p53 ()
Telomerase () 7 347.7 (193.3e502.2) 3 out of 7 (43.0%)
p53 (þ)
Telomerase (þ) 16 248.4 (162.6e334.3) 10 out of 16 (62.5%)
p53 ()
Telomerase (þ) 21 253.1 (187.1e319.2) 13 out of 21 (62%)
p53 (þ)
Overall 52 276.4 (234.8e317.9) 30 out of 52 (58.0%)
Probability of survival (Kaplan-Meyer curve; p = 0.03)
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Figure 1 Probability of survival with respect to telomerase
activity in lung tumour, observed in the studied group.
1358 T. Targowski et al.open lung biopsy, the final stage of cancer stage was
determined by a combination of pathomorphological and
clinical findings, according to the current TNM classification
for lung cancer staging.1,18
Relationships were assessed between patient survival on
one hand and patient age and sex, telomerase activity in
primary tumour, serum p53 protein levels and the clinical
stage of NSCLC on the other, employing the Cox hazard
analysis. The 95% confidence interval (CI) was set and p
value 0.05 was considered as statistically significant. All
of the statistical analyses were performed with the STA-
TISTICA PL 7.0 program (serial No. AAAP510C860213FA).
The study protocol was approved by the Ethics Committee
of the Military Medical Chamber.
Results
The analyzed group comprised 52 patients [15 women and 37
men, mean age e 66.4 (95 CI: 63.1e69.8) years] with newly
diagnosed, non-small cell lung cancer, including 28 patients
with stage IIIB and 24 patients with stage IV of the disease.
Cytological diagnosis of lung tumour was established from
TFNB results in 45 (86.5%) patients. In four cases, histological
diagnosis of tumour was done after open lung biopsy and in
three cases, after bronchial brushing during bronchoscopy.
Detectable telomerase activity was found in 42 (81%) aspi-
rates, obtained during the TFNB. Detectable telomerase
activity was found in 29 (80.5%), out of 36 histologically
unspecified non-small cell lung cancers, 4, out of 6 (66%)
squamous cell cancers and in 9, out of 10 adenocarcinomas.
Elevated serum p53 protein concentrations were observed in
28 (54%), out of 52 patients, including 23 cases of unspecified
NSCLC, 1 case of squamous cell carcinoma and 4 cases of
adenocarcinoma. All the patients were treated by oncolo-
gists, according to the evidence-based medicine principles.
Forty patients were treated only with chemotherapy and/or
radiotherapy. The best supportive therapy was conducted in
the remaining twelve patients (3 patients didn’t give consent
for more aggressive treatment, 2 were older than 80, 2 had
massive pleural effusions, and last 5 patients had severe
chronic obstructive pulmonary disease).
During the study period, 23 (62%) patients died, out of 37
patients with detectable telomerase activity, 7 (47%), outof 15 without detectable activity of telomerase in primary
tumour, 16 (57%), out of 28 subjects with high serum levels
of p53 protein and 14 (58%), out of 24 without increased
serum p53 levels (Table 1). The mean periods of survival,
according to telomerase activity and p53 protein concen-
trations, are presented in Table 1.
It was shown that the presence of telomerase activity in
aspirates derived from primary lung tumour, opposite to
increased levels of p53 protein in serum, is a significant
predictor of survival in patients with advanced, non-
operable NSCLC (Figs. 1 and 2). Neither were there any
significant differences in the probability of survival among 4
subgroups of patients, divided with respect to increased
serum p53 protein levels and/or telomerase activity in
cancer tissue (Fig. 3).
A statistically significant relationship was observed in
Cox hazard analysis between the time of survival and the
quantitatively measured telomerase activity levels (in RTA
units). There was no such relationship though between the
survival period on the one hand and serum levels of p53
protein, sex, age, primary lung tumour size (T feature),
lymph node occupation or the presence of distant metas-
tases on the other (Table 2).
Table 2 Cox hazard analysis of the influence of selected
factors on the survival in patients with advanced NSCLC
(pZ 0.046*).
p
Relative telomerase activity
Mean (95%CI) 0.007*
34.7 (21.6e47.9) units
Serum level of p53
Mean (95%CI) 0.16
153.0 (97.7e208.4) pg/ml
Age
Mean (95% CI) 0.5
66.4 (63.1e69.8) years
Sex (number of cases)
Female e 15 0.6
Male e 37
T (number of cases)
T1 e 5 0.09
T2 e 21
T3 e 10
T4 e 16
N (number of cases)
N0 e 10 0.1
N1 e 14
N2 e 13
N3 e 15
M (number of cases)
M0 e 28 0.9
M1 e 24
* Significant p value 0.05.
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Figure 2 Probability of survival with respect to increased
serum levels of p53 protein in the studied group during
observation period.
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In the last decade, numerous studies have shown highly
increased telomerase activity in more than 80% of different
carcinomas, while either no or very low expression in
normal tissues.3e5,9,19e22 In patients with lung carcinoma,
high-telomerase activity has been observed in sputum,
bronchial washing and brushing specimens obtained during
bronchofibroscopy.2,22 In our previous studies we proved
that assessment of telomerase activity in lung infiltrations
is a useful supplemental procedure in differentiation
between malignant and benign tumours.23 It is thought then
that telomerase, as an enzyme responsible for unlimited
replication of genetic material inside cancer cells and
incomplete cell divisions, could be a molecular prognostic
factor. Fujita et al.24 observed that strong and moderate
expression of human telomerase reverse transcriptase
mRNA (hTERT) in resected NSCLC was a prognostic factor of
survival with predictive power similar to that of lymph nodeProbability of survival (Kaplan-Meyer curve; p = 0.2)
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Figure 3 Probability of survival with respect to increased
serum levels of p53 protein and telomerase activity in lung
tumour in the studied group during observation period.status, pathomorphological TNM stage and the age of
patients. Some authors did not find any association
between clinicopathological features of lung cancer and
hTERT status, however, they observed longer survival
periods of patients without telomerase activity in primary
tumours.25 So far, telomerase prognostic value in lung
cancer has been studied on specimens derived from less
advanced, surgically resectable tumours.4,24,26,27 Moreover
in normal cells and tissues, the levels of wild type of p53
are very low, whereas in malignant tissues and cancer lines,
a mutated p53 polypeptide is often detectable in high
concentrations.28e30,33 It is believed that more advanced
stages of lung cancer could be associated with higher p53
activity in blood serum.29 So far, several studies have been
conducted in which the presence of p53 antibodies, the
levels of p53 protein or expression of p53 suppressor gene
correlated to various clinical parameters in patients with
cancer.29,31e36 Most of all, the studies on the prognostic
value of p53 in lung cancer were conducted in patients who
had undergone surgical treatment because of non-small cell
lung cancer.31,32,35 There are only a few publications on the
prognostic role of p53 in patients with advanced lung
cancer.29
In this study, we tried to assess if telomerase activity in
aspirates, derived from primary lung tumours, and serum
levels of p53 protein could be valuable prognostic factors in
1360 T. Targowski et al.patients with advanced non-small cell lung cancer (stages
IIIB plus IV). Following Fujita et al.24 we selected some
variables for analysis of survival. It was revealed that only
telomerase activity correlated significantly with obtained
lifetime. There was no significant relationship between the
survival period and serum levels of p53 protein, the age and
sex of patients, primary tumour size (T), lymph node status
(N) or the presence of distant metastases in the studied
group (Table 2). We may conclude then that telomerase
activity in advanced primary non-small cell lung cancer is
a better predictor of patient survival than serum levels of
p53 protein. The assessment of telomerase activity
supplements the prognosis of survival in the course of
advanced, non-resectable NSCLC.
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